CENTENNIAL, Colo.--(BUSINESS WIRE)--Osiris Therapeutics and AlloSource announced today that they have reached a multi-year agreement for the supply of orthopedic tissue. Under the terms of the agreement, AlloSource will provide bone matrix to Osiris for use in the production of its Osteocel product line. Osteocel will be available from AlloSource to patients in all of AlloSource’s donor areas across the country. AlloSource is one of the nation’s largest non-profit providers of bone and soft tissue allografts, as well as allograft skin for burn applications, for use in surgical procedures.
